A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Early-stage clinical data with CanSino Biologics' inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies against SARS-CoV-2 at a dose well below that required with ...

Most COVID-19 vaccines are injected into the arm or leg, and while they are effective at reducing illness and death, they do not halt transmission. The new trial will evaluate the safety and efficacy ...

Ocugen Inc. has received IND clearance from the FDA for OCU-500, an inhaled mucosal vaccine for COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor and conduct a ...

Chinese biotech CanSino Biologics said in April it was starting trials of an inhaled COVID-19 vaccine, while others looking at nasal or inhaled delivery include Cadogenix, Phage Novo Bio ...

This is a critical step toward the initiation of the Phase 1 clinical trial for OCU500—an inhaled mucosal vaccine for COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

Targeting more than one viral protein has shown in the recent past to be effective: one of the mRNA COVID-19 shots was a bivalent vaccine that worked against two different strains of the virus.

Covid vaccines saved lives. Lots of them. Research by the World Health Organization (WHO) now puts the number at 475,000 in the UK with many more kept out of hospital or off a ventilator.

When news breaks, you need to understand what matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.